China continues industry probe

Share this article:

China's scrutiny of the drug industry continues. The Wall Street Journal reports that Roche announced government authorities from China's State Administration for Industry and Commerce, an agency which oversees marketing and antitrust, visited a site in Hangzhou.

Thursday's news follows last week's announcement that the Ministry of Public Security accused GlaxoSmithKline of bribing HCPs to stimulate prescriptions.

AstraZeneca, Sanofi and Bayer have also come under review over the last year.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs


Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.